BACKGROUND: This study was conducted to assess the antitumour activity of docetaxel in combination with doxorubicin for neoadjuvant therapy of patients with breast cancer. PATIENTS AND METHODS: Forty-eight women were treated with intravenous doxorubicin 50 mg/m(2) over 15 min followed by a 1-h infusion of docetaxel 75 mg/m(2) every 3 weeks for six cycles. Dexamethasone or prednisolone premedication was allowed. Granulocyte colony-stimulating factor was not allowed as primary prophylaxis. The primary end point was the pathologically documented complete response rate (pathological response). RESULTS: The mean relative dose intensity calculated for four or more cycles was 0.99 for doxorubicin and 0.99 for docetaxel. Overall, the pathological response rate was 13%. There were 11 complete and 29 partial clinical responses for an overall response rate of 85% [95% confidence interval (CI) 75% to 95%] in the evaluable population (n = 47). Disease-free and overall survival rates were 85% (95% CI 71% to 94%) and 96% (95% CI 85% to 99%), respectively, after a median follow-up of 36.6 months. Grade 3/4 neutropenia was observed in 65% of patients and 17% reported grade 4 febrile neutropenia. CONCLUSIONS: Docetaxel and doxorubicin is an effective and well-tolerated combination in the neoadjuvant therapy of breast cancer. Future controlled trials are warranted to investigate the best schedules and to correlate response with biological factors.
BACKGROUND: This study was conducted to assess the antitumour activity of docetaxel in combination with doxorubicin for neoadjuvant therapy of patients with breast cancer. PATIENTS AND METHODS: Forty-eight women were treated with intravenous doxorubicin 50 mg/m(2) over 15 min followed by a 1-h infusion of docetaxel 75 mg/m(2) every 3 weeks for six cycles. Dexamethasone or prednisolone premedication was allowed. Granulocyte colony-stimulating factor was not allowed as primary prophylaxis. The primary end point was the pathologically documented complete response rate (pathological response). RESULTS: The mean relative dose intensity calculated for four or more cycles was 0.99 for doxorubicin and 0.99 for docetaxel. Overall, the pathological response rate was 13%. There were 11 complete and 29 partial clinical responses for an overall response rate of 85% [95% confidence interval (CI) 75% to 95%] in the evaluable population (n = 47). Disease-free and overall survival rates were 85% (95% CI 71% to 94%) and 96% (95% CI 85% to 99%), respectively, after a median follow-up of 36.6 months. Grade 3/4 neutropenia was observed in 65% of patients and 17% reported grade 4 febrile neutropenia. CONCLUSIONS:Docetaxel and doxorubicin is an effective and well-tolerated combination in the neoadjuvant therapy of breast cancer. Future controlled trials are warranted to investigate the best schedules and to correlate response with biological factors.
Authors: Nicolas Magné; Rémy Largillier; Pierre-Yves Marcy; Jacques Magné; Moïse Namer Journal: Support Care Cancer Date: 2005-03-30 Impact factor: 3.603
Authors: Jesus García-Mata; Andres García-Palomo; Lourdes Calvo; Ramon Mel; Juan Jesus Cruz; Manuel Ramos Journal: Clin Transl Oncol Date: 2008-11 Impact factor: 3.405
Authors: Jürgen Eckes; Oliver Schmah; Jan W Siebers; Ursula Groh; Stefan Zschiedrich; Beate Rautenberg; Annette Hasenburg; Martin Jansen; Martin J Hug; Karl Winkler; Gerhard Pütz Journal: BMC Cancer Date: 2011-08-04 Impact factor: 4.430
Authors: Daniel G Tiezzi; Jurandyr M Andrade; Alfredo Ribeiro-Silva; Fábio E Zola; Heitor R C Marana; Marcelo G Tiezzi Journal: BMC Cancer Date: 2007-02-26 Impact factor: 4.430
Authors: P F Conte; S Donati; A Gennari; V Guarneri; C Orlandini; M Rondini; M Roncella; L Marini; P Collecchi; P Viacava; A G Naccarato; R Degli Esposti; S Bonardi; A Bottini; S Saracchini; S Tumolo; G Gullo; A Santoro; L Crino Journal: Br J Cancer Date: 2005-08-22 Impact factor: 7.640